Chetan Bettegowda, M.D., Ph.D.
Languages: English, Kannada
Brain Tumors, CyberKnife and Stereotactic Radiosurgery, Gliomas, Meningiomas, Metastatic Brain Tumors, Neurosurgery, Pituitary Tumors, Skull Base Surgery, Skull Base Tumors, Spinal Cord Tumors, Spinal Tumors, Stereotactic Radiosurgery, Trigeminal Neuralgia, Von Hippel-Lindau (VHL) ...read more
Identify key genetic pathways that are altered in brain tumors; Developing clinical trials to selectively target these pathways; Developing targeted therapies for patients with primary and metastatic tumors of the brain and spine; Ongoing clinical protocol to develop a simple blood test that can detect and monitor disease burden in patients with tumors affecting the central nervous system ...read more
Dr. Chetan Bettegowda offers comprehensive treatments for adult patients with benign and malignant brain tumors, specializing in the treatment of patients with primary brain tumors such as gliomas, meningiomas and pituitary tumors. He performs both open surgery and stereotactic radiosurgery for patients with metastatic tumors to the brain, and also provides stereotactic radiosurgery for other neurological disorders, including spinal tumors, trigeminal neuralgia and skull-base tumors.
Bringing personalized medicine to the forefront of treatment for patients with brain and spinal tumors is of specific interest to Dr. Chetan Bettegowda. His research is dedicated to developing targeted therapies for patients with primary and metastatic tumors of the brain and spine. As part of this research, he has helped identify key genetic pathways that are altered in brain tumors, and he is developing clinical trials to selectively target these pathways. Dr. Bettegowda is also spearheading an ongoing clinical protocol to develop a simple blood test that can detect and monitor disease burden in patients with tumors affecting the central nervous system
Ongoing clinical protocol to develop a simple blood test that can detect and monitor disease burden in patients with tumors affecting the central nervous system
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma. IRB Number: IRB00079861.
This study plans to test overall survival in patients treated with the medication Toca 511 (vocimagene amiretrorepvec), combined with Toca FC (flucytosine) tablets. This combination medication is being used to test to see if it works well for treating high grade gliomas patients whom have suffered a recurrence of their tumor
Trigeminal Neuralgia Surgery: Q&A
Trigeminal Neuralgia Surgery: What You Need to Know
Trigeminal Neuralgia Surgery | Michelle's Story
Malignant Brain Tumor Surgery - What You Need to Know
Malignant Brain Tumor Clinical Trials - What You Need to Know
Doorways to Discovery: Liquid Biopsy to Track Cancer
Individualized Care Through Translocation Testing, NeuroLogic (Winter 2021)
A Liquid Biopsy to Track Cancer and Avoid Surgery, Doorways to Discovery (November 2014)
Tumor Tracker, Hopkins Medicine Magazine, Spring/Summer 2014
The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.